NeRD: a Multichannel Neural Network to Predict Cellular Response of Drugs by Integrating Multidimensional Data

Overview

Journal BMC Med

Publisher Biomed Central

Specialty General Medicine

Date 2022 Oct 16

PMID 36244991

Authors

Xiaoxiao Cheng

Chong Dai

Yuqi Wen

Xiaoqi Wang

Xiaochen Bo

Song He

Shaoliang Peng

Affiliations

Soon will be listed here.

Abstract

Background: Considering the heterogeneity of tumors, it is a key issue in precision medicine to predict the drug response of each individual. The accumulation of various types of drug informatics and multi-omics data facilitates the development of efficient models for drug response prediction. However, the selection of high-quality data sources and the design of suitable methods remain a challenge.

Methods: In this paper, we design NeRD, a multidimensional data integration model based on the PRISM drug response database, to predict the cellular response of drugs. Four feature extractors, including drug structure extractor (DSE), molecular fingerprint extractor (MFE), miRNA expression extractor (mEE), and copy number extractor (CNE), are designed for different types and dimensions of data. A fully connected network is used to fuse all features and make predictions.

Results: Experimental results demonstrate the effective integration of the global and local structural features of drugs, as well as the features of cell lines from different omics data. For all metrics tested on the PRISM database, NeRD surpassed previous approaches. We also verified that NeRD has strong reliability in the prediction results of new samples. Moreover, unlike other algorithms, when the amount of training data was reduced, NeRD maintained stable performance.

Conclusions: NeRD's feature fusion provides a new idea for drug response prediction, which is of great significance for precise cancer treatment.

Citing Articles

DD-PRiSM: a deep learning framework for decomposition and prediction of synergistic drug combinations.

Jin I, Lee S, Schmuhalek M, Nam H Brief Bioinform. 2025; 26(1.

PMID: 39800875 PMC: 11725392. DOI: 10.1093/bib/bbae717.

TransCDR: a deep learning model for enhancing the generalizability of drug activity prediction through transfer learning and multimodal data fusion.

Xia X, Zhu C, Zhong F, Liu L BMC Biol. 2024; 22(1):227.

PMID: 39385185 PMC: 11462810. DOI: 10.1186/s12915-024-02023-8.

Multi-output prediction of dose-response curves enables drug repositioning and biomarker discovery.

Gutierrez J, Lau E, Dharmapalan S, Parker M, Chen Y, Alvarez M NPJ Precis Oncol. 2024; 8(1):209.

PMID: 39304771 PMC: 11415488. DOI: 10.1038/s41698-024-00691-x.

A comprehensive benchmarking of machine learning algorithms and dimensionality reduction methods for drug sensitivity prediction.

Eckhart L, Lenhof K, Rolli L, Lenhof H Brief Bioinform. 2024; 25(4).

PMID: 38797968 PMC: 11128483. DOI: 10.1093/bib/bbae242.

CPADS: a web tool for comprehensive pancancer analysis of drug sensitivity.

Li K, Yang H, Lin A, Xie J, Wang H, Zhou J Brief Bioinform. 2024; 25(3).

PMID: 38770717 PMC: 11106634. DOI: 10.1093/bib/bbae237.

References

Chen Y, Zhang L . How much can deep learning improve prediction of the responses to drugs in cancer cell lines?. Brief Bioinform. 2021; 23(1). DOI: 10.1093/bib/bbab378. View

Chong C, Janne P . The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med. 2013; 19(11):1389-400. PMC: 4049336. DOI: 10.1038/nm.3388. View

Liu Q, Hu Z, Jiang R, Zhou M . DeepCDR: a hybrid graph convolutional network for predicting cancer drug response. Bioinformatics. 2020; 36(Suppl_2):i911-i918. DOI: 10.1093/bioinformatics/btaa822. View

Huang C, Clayton E, Matyunina L, McDonald L, Benigno B, Vannberg F . Machine learning predicts individual cancer patient responses to therapeutic drugs with high accuracy. Sci Rep. 2018; 8(1):16444. PMC: 6219522. DOI: 10.1038/s41598-018-34753-5. View

Huang E, Bhope A, Lim J, Sinha S, Emad A . Tissue-guided LASSO for prediction of clinical drug response using preclinical samples. PLoS Comput Biol. 2020; 16(1):e1007607. PMC: 6975549. DOI: 10.1371/journal.pcbi.1007607. View

Shoemaker R . The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006; 6(10):813-23. DOI: 10.1038/nrc1951. View

Hyman D, Taylor B, Baselga J . Implementing Genome-Driven Oncology. Cell. 2017; 168(4):584-599. PMC: 5463457. DOI: 10.1016/j.cell.2016.12.015. View

Costello J, Heiser L, Georgii E, Gonen M, Menden M, Wang N . A community effort to assess and improve drug sensitivity prediction algorithms. Nat Biotechnol. 2014; 32(12):1202-12. PMC: 4547623. DOI: 10.1038/nbt.2877. View

Cohen-Solal K, Kaufman H, Lasfar A . Transcription factors as critical players in melanoma invasiveness, drug resistance, and opportunities for therapeutic drug development. Pigment Cell Melanoma Res. 2017; 31(2):241-252. DOI: 10.1111/pcmr.12666. View

10.

Xie R, Wen J, Quitadamo A, Cheng J, Shi X . A deep auto-encoder model for gene expression prediction. BMC Genomics. 2017; 18(Suppl 9):845. PMC: 5773895. DOI: 10.1186/s12864-017-4226-0. View

11.

Maquoi E, Sounni N, Devy L, Olivier F, Frankenne F, Krell H . Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor. Clin Cancer Res. 2004; 10(12 Pt 1):4038-47. DOI: 10.1158/1078-0432.CCR-04-0125. View

12.

Azuaje F . Computational models for predicting drug responses in cancer research. Brief Bioinform. 2016; 18(5):820-829. PMC: 5862310. DOI: 10.1093/bib/bbw065. View

13.

Wong H, Lewies A, Haigh M, Viljoen J, Wentzel J, Haynes R . Anti-Melanoma Activities of Artemisone and Prenylated Amino-Artemisinins in Combination With Known Anticancer Drugs. Front Pharmacol. 2020; 11:558894. PMC: 7552967. DOI: 10.3389/fphar.2020.558894. View

14.

Kumagai S, Koyama S, Nishikawa H . Antitumour immunity regulated by aberrant ERBB family signalling. Nat Rev Cancer. 2021; 21(3):181-197. DOI: 10.1038/s41568-020-00322-0. View

15.

Parca L, Pepe G, Pietrosanto M, Galvan G, Galli L, Palmeri A . Modeling cancer drug response through drug-specific informative genes. Sci Rep. 2019; 9(1):15222. PMC: 6811538. DOI: 10.1038/s41598-019-50720-0. View

16.

Rousseau A, Bertolotti A . Regulation of proteasome assembly and activity in health and disease. Nat Rev Mol Cell Biol. 2018; 19(11):697-712. DOI: 10.1038/s41580-018-0040-z. View

17.

Menden M, Iorio F, Garnett M, McDermott U, Benes C, Ballester P . Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties. PLoS One. 2013; 8(4):e61318. PMC: 3640019. DOI: 10.1371/journal.pone.0061318. View

18.

Kim S, Chen J, Cheng T, Gindulyte A, He J, He S . PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res. 2020; 49(D1):D1388-D1395. PMC: 7778930. DOI: 10.1093/nar/gkaa971. View

19.

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim S . The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-7. PMC: 3320027. DOI: 10.1038/nature11003. View

20.

Julien S, Dube N, Hardy S, Tremblay M . Inside the human cancer tyrosine phosphatome. Nat Rev Cancer. 2010; 11(1):35-49. DOI: 10.1038/nrc2980. View